KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Assets (2016 - 2025)

Historic Assets for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $1.2 billion.

  • Novavax's Assets fell 3110.07% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 3110.07%. This contributed to the annual value of $1.6 billion for FY2024, which is 1318.91% down from last year.
  • According to the latest figures from Q3 2025, Novavax's Assets is $1.2 billion, which was down 3110.07% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Novavax's Assets registered a high of $2.8 billion during Q1 2022, and its lowest value of $1.2 billion during Q3 2025.
  • Moreover, its 5-year median value for Assets was $1.8 billion (2023), whereas its average is $2.0 billion.
  • Its Assets has fluctuated over the past 5 years, first soared by 69506.87% in 2021, then plummeted by 4558.14% in 2023.
  • Quarter analysis of 5 years shows Novavax's Assets stood at $2.6 billion in 2021, then fell by 12.34% to $2.3 billion in 2022, then fell by 20.42% to $1.8 billion in 2023, then decreased by 13.19% to $1.6 billion in 2024, then decreased by 24.39% to $1.2 billion in 2025.
  • Its Assets stands at $1.2 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.